LifeArc announces partnership with Elpida Therapeutics to accelerate gene therapies for ultra-rare diseas

LifeArc is teaming with Elpida Therapeutics to accelerate gene therapies for ultra-rare diseases by providing tailored clinical, translational and regulatory expertise alongside financial support. The collaboration concentrates on programs in the UK and Europe, with the aim of shortening development timelines and sharing learnings to improve pathways for rare therapies. Elpida Therapeutics was founded by Terry and Georgia Pirovolakis after their son Michael's SPG50 diagnosis, and the organization is advancing Melpida, a gene therapy candidate for SPG50. Early-stage trials have already progressed in the US and Europe as part of the alliance.

Under the deal, LifeArc and Elpida will support three programmes at different development stages, focusing on the UK and Europe to accelerate progress. The SPG50 program Melpida has begun enrolling in its US pivotal Phase III trial in April this year, with the goal of FDA approval and US access by early 2028. Elpida is also building a pipeline of therapies for other ultra-rare conditions with significant unmet needs. LifeArc provides translational science, regulatory guidance and financial backing to shorten development timelines and improve patient access. The collaboration is designed to share learnings that could streamline future pathways for rare therapies.